Executive Director, Portfolio Lead, Global Discovery Chemistry at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Ph.D. in organic or medicinal chemistry
Minimum of 15 years of relevant post-graduate experience in the pharmaceutical or biotechnology sectors
Demonstrated success in leading medicinal chemistry teams that have advanced innovative drug candidates to clinical development
Experience with one or more chemical modalities such as antibody-drug conjugates (ADCs), monovalent or bivalent protein degraders, oligonucleotides, and/or macrocyclic peptides (preferred)
Proven ability to

Responsibilities

Provide strategic leadership and oversee the portfolio delivery of multiple discovery chemistry programs, ensuring alignment with organizational objectives and production of high-quality, differentiated small molecule drugs
Manage site operations for Global Discovery Chemistry team at the Cambridge, MA location, upholding organizational standards, ensuring efficient execution of scientific initiatives, promoting a productive work environment, and supporting local teams in meeting strategic goals
Act as a mentor to leaders, teams, and scientists, encouraging adoption and implementation of AI/ML tools and other innovative technologies to accelerate new medicine development
Promote collaboration and accountability within matrix and line teams to deliver impactful scientific results
Ensure strategic alignment and progress across one or more therapeutic areas within the BMS portfolio

Skills

Medicinal Chemistry

Drug Discovery

Organic Synthesis

Portfolio Management

Strategic Planning

Team Leadership

Matrix Management

Therapeutic Chemistry

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free